Winski S L, Faig M, Bianchet M A, Siegel D, Swann E, Fung K, Duncan M W, Moody C J, Amzel L M, Ross D
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
Biochemistry. 2001 Dec 18;40(50):15135-42. doi: 10.1021/bi011324i.
We report the characterization of 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione (ES936) as a mechanism-based inhibitor of NQO1. Inactivation of NQO1 by ES936 was time- and concentration-dependent and required the presence of a pyridine nucleotide cofactor consistent with a need for metabolic activation. That ES936 was an efficient inhibitor was demonstrated in these studies by the low partition ratio (1.40 +/- 0.03). The orientation of ES936 in the active site of NQO1 was examined by X-ray crystallography and found to be opposite to that observed for other indolequinones acting as substrates. ES936 was oriented in such a manner that, after enzymatic reduction and loss of a nitrophenol leaving group, a reactive iminium species was located in close proximity to nucleophilic His 162 and Tyr 127 and Tyr 129 residues in the active site. To determine if ES936 was covalently modifying NQO1, ES936-treated protein was analyzed by electrospray ionization liquid chromatography/mass spectrometry (ESI-LC/MS). The control NQO1 protein had a mass of 30864 +/- 6 Da (n = 20, theoretical, 30868.6 Da) which increased by 217 Da after ES936 treatment (31081 +/- 7 Da, n = 20) in the presence of NADH. The shift in mass was consistent with adduction of NQO1 by the reactive iminium derived from ES936 (M + 218 Da). Chymotryptic digestion of the protein followed by LC/MS analysis located a tetrapeptide spanning amino acids 126-129 which was adducted with the reactive iminium species derived from ES936. LC/MS/MS analysis of the peptide fragment confirmed adduction of either Tyr 127 or Tyr 129 residues. This work demonstrates that ES936 is a potent mechanism-based inhibitor of NQO1 and may be a useful tool in defining the role of NQO1 in cellular systems and in vivo.
我们报告了5-甲氧基-1,2-二甲基-3-[(4-硝基苯氧基)甲基]吲哚-4,7-二酮(ES936)作为NQO1的基于机制的抑制剂的特性。ES936对NQO1的失活具有时间和浓度依赖性,并且需要吡啶核苷酸辅因子的存在,这与代谢活化的需求一致。在这些研究中,低分配比(1.40±0.03)证明了ES936是一种有效的抑制剂。通过X射线晶体学研究了ES936在NQO1活性位点的取向,发现其与作为底物的其他吲哚醌所观察到的取向相反。ES936的取向方式使得在酶促还原和硝基苯酚离去基团丢失后,一个反应性亚胺物种紧邻活性位点中的亲核性组氨酸162、酪氨酸127和酪氨酸129残基。为了确定ES936是否共价修饰NQO1,通过电喷雾电离液相色谱/质谱(ESI-LC/MS)分析了经ES936处理的蛋白质。对照NQO1蛋白的质量为30864±6 Da(n = 20,理论值为30868.6 Da),在存在NADH的情况下经ES936处理后增加了217 Da(31081±7 Da,n = 20)。质量的变化与ES936衍生的反应性亚胺对NQO1的加成(M + 218 Da)一致。对该蛋白质进行胰凝乳蛋白酶消化,然后进行LC/MS分析,定位到一个跨越氨基酸126 - 129的四肽,该四肽与ES936衍生的反应性亚胺物种加成。对该肽片段的LC/MS/MS分析证实了酪氨酸127或酪氨酸129残基的加成。这项工作表明ES936是一种有效的基于机制的NQO1抑制剂,可能是确定NQO1在细胞系统和体内作用的有用工具。